US OptionsDetailed Quotes
MREO250516C4000
- 0.05
- 0.000.00%
15min DelayClose May 2 16:00 ET
0.05High0.05Low
0.05Open0.05Pre Close30 Volume813 Open Interest4.00Strike Price150.00Turnover163.92%IV51.69%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier13DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1335Delta0.2543Gamma53.40Leverage Ratio-0.0066Theta0.0001Rho7.13Eff Leverage0.0011Vega
Mereo BioPharma Stock Discussion
Mereo BioPharma Secures 3-Year Cash Runway While Pushing Phase 3 Studies Forward
Larger Image: tradingview.com...
$Mereo BioPharma (MREO.US)$
Mereo spikes after mid-stage data for Ultragenyx-partnered bone disorder therapy
$Merck & Co (MRK.US)$ x $Immunovant (IMVT.US)$
$Eli Lilly and Co (LLY.US)$ x $Cytokinetics (CYTK.US)$ (and soon)
$Regeneron Pharmaceuticals (REGN.US)$ x $Apellis Pharmaceuticals (APLS.US)$ (panache & brash)
$Gilead Sciences (GILD.US)$ x % $Madrigal Pharmaceuticals (MDGL.US)$ (liver king)
$Bristol-Myers Squibb (BMY.US)$ x $Iovance Biotherapeutics (IOVA.US)$ (cell Tx boost needed)
$Eli Lilly and Co (LLY.US)$ x $Merus (MRUS.US)$ (partner n...
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...
No comment yet